IPO
MBD Co., Ltd.
엠비디
What the company does
MBD develops automated experiment screening systems (ASFA) and offers drug-evaluation CRO services using patient-derived 3D tumoroids. It also provides OncoSensi, a functional precision-medicine test that measures patient cancer cells' drug response.
- Market
- KOSDAQ
- Price range
- ₩9,600 – ₩11,700
- Offer price
- Not set yet
- Subscription
- Nov 12 – Nov 13
- Payment date
- Nov 17, 2026
- Listing
- Not set yet
- Shares offered
- 2,000,000
- Raising
- ₩19.2B
Lead managers: Hana Securities
Filings
- [기재정정]증권신고서(지분증권)Oct 15, 2026Open on DART ↗
- [기재정정]증권신고서(지분증권)Sep 18, 2026Open on DART ↗
- 증권신고서(지분증권)Aug 28, 2026Open on DART ↗
How a Korean IPO works: institutions bid first (the demand forecast), which sets the final offer price; then individuals subscribe for two days through the lead managers' brokerage accounts; shares start trading on the listing date.
Dates and prices can change until the final terms are filed. Not financial advice. · Updated Oct 27, 2026 · IPO calendar